22:36 , Feb 9, 2018 |  BioCentury  |  Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
16:24 , Feb 9, 2018 |  BC Week In Review  |  Company News

Intarcia terminates late-stage diabetes trials

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov. The company received a complete response letter from FDA in September for an NDA seeking approval...
23:40 , Feb 2, 2018 |  BC Extra  |  Company News

Intarcia terminates Phase III diabetes trials

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials earlier this week evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov. The company received a complete response letter from FDA in September for an...
21:52 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends label update to AZ's Bydureon

EMA's CHMP recommended expanding the label of Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include treatment of Type II diabetes in combination with other glucose lowering treatments, including basal insulin, when use of Bydureon...
19:54 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Intarcia gets CRL for Type II diabetes candidate ITCA 650

FDA issued a complete response letter to an NDA for ITCA 650 from Intarcia Therapeutics Inc. (Boston, Mass.) to treat Type II diabetes. The company said it plans to resubmit the NDA after meeting with...
23:09 , Aug 16, 2017 |  BC Week In Review  |  Clinical News

AZ's Bydureon improves motor function in Phase II for PD

Data published in The Lancet showed that diabetes drug Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) met the primary endpoint in the Phase II EXENATIDE-PD trial to treat moderate Parkinson’s disease. In the 60-patient trial,...
22:01 , Jun 21, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Polymers PEG-based hydrogel microspheres that release peptide drugs continuously over several weeks could help treat Type II diabetes and other chronic diseases with once-monthly dosing. The microspheres are linked to peptide therapeutics via a carbamate...
17:15 , Jun 2, 2017 |  BC Week In Review  |  Company News

AZ and Harvard Pilgrim sign two outcomes-based drug pricing contracts

Regional insurer Harvard Pilgrim Health Care Inc. (Boston, Mass.) signed two outcomes-based drug pricing contracts with AstraZeneca plc (LSE:AZN; NYSE:AZN). The insurer signed a three-year contract for AZ’s Brilinta ticagrelor, which is marketed in the U.S....
20:06 , May 19, 2017 |  BC Week In Review  |  Company News

3SBio acquires China rights to Lilly's Humulin

Eli Lilly and Co. (NYSE:LLY) granted 3SBio Inc. (HKSE:1530) exclusive rights to distribute and promote its diabetes drug Humulin in China, beginning July 1. Lilly's China unit will be responsible for manufacturing the drug, while 3SBio...
17:14 , May 19, 2017 |  BioCentury  |  Strategy

Contracting 2.0

Pricing doesn’t always cause business discontinuities -- but it’s always the double-edged sword at the center of the action, helping innovators and hobbling laggards. Discount brokers revolutionized consumer investing; discounted long-distance ultimately destroyed AT&T. Price...